Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief scientific officer Bill Love speaks to Proactive after results from a study into its C. Difficile platform NTCD-M3 were published in the Microbiology Spectrum journal.
Love explains what makes the platform so promising from Destiny's point of view, before going on to reveal more about the plans for bringing NTCD-M3 to the market.